Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin for reinduction of radioiodine uptake in advanced non-medullary thyroid cancer
NL-OMON59359Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of digoxin in Non-medullary thyroid cancer (NMTC) and thyroid cancer, sponsored by Radboud University Medical Center. Primary endpoint: Reinduction of radioiodine uptake. Started Nov 2022; status: completed.
02
Drugs
digoxin
03
Conditions
Non-medullary thyroid cancer (NMTC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON59359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59359.